<DOC>
	<DOC>NCT01731275</DOC>
	<brief_summary>To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single ascending dose (SAD) administration of E6011 in Japanese healthy volunteers.</brief_summary>
	<brief_title>A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)</brief_title>
	<detailed_description />
	<criteria>Inclusion criteria; 1. Nonsmoking Japanese male subjects aged &gt;= 20 to less than 45 years 2. BMI at screening is &gt;= 18.5 kg/m2 to less than 25.0 kg/m^2 3. Males who have not had a successful vasectomy and their female partners must agree to practice highly effective contraception throughout the study period. Exclusion criteria; 1. Has been treated with biologic products (except for immunoglobulin preparation) 2. Have received immunoglobulin or blood preparation within 6 months before the study drug administration 3. Received inoculation within 4 weeks before the study drug administration 4. Has a history of autoimmune disease or immunodeficiency 5. Has a clinically significant angioedema, hematemesis, anal hemorrhage, or hemoptysis 6. Has a history of acute myocardial infarction, cerebral infarction, cerebral hemorrhage, or arteriosclerosis obliterate 7. With gross hematuria, occult bleeding in urine (&gt;=1+) and urine protein (&gt;=1+) , or either of (&gt;=2+) at screening 8. Has a clinically significant vasculitis (e.g., multiple mononeuropathy) 9. Known to be positive for human immunodeficiency virus (HIV antigen and antibody), hepatitis B virus surface antigen (HBs antigen), hepatitis B virus surface antibody (HBs antibody), hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) antibody, or syphilis serology test 10. Known to be positive for human Tcell lymphotropic virus type 1 (HTVL1) antibody at screening 11. Known to be positive for QuantiFERONTB Gold Test 12. Treated with ethical drug(s) within 4 weeks before the study drug administration (except for disinfectants, eye drops) 13. Treated with nonprescription drug(s) within 2 weeks before the study drug administration (except for disinfectants, eye drops) 14. Has participated in another clinical trial and received an investigational drug or device within 6 months before the study drug administration 15. Received blood transfusion within 1 year, 400 mL or more whole blood donation within 12 weeks, or 200 mL or more whole blood donation within 4 weeks, or blood constituent donation within 2 weeks before the study drug administration.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Healthy volunteers</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>anti-E6011 antibody</keyword>
</DOC>